CKD273, a new proteomics classifier assessing CKD and its prognosis

Argiles, A. et al. (2013) CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS ONE, 8(5), e62837. (doi: 10.1371/journal.pone.0062837) (PMID:23690958) (PMCID:PMC3653906)

135112.pdf - Published Version
Available under License Creative Commons Attribution.



National Kidney Foundation CKD staging has allowed uniformity in studies on CKD. However, early diagnosis and predicting progression to end stage renal disease are yet to be improved. Seventy six patients with different levels of CKD, including outpatients and dialysed patients were studied for transcriptome, metabolome and proteome description. High resolution urinary proteome analysis was blindly performed in the 53 non-anuric out of the 76 CKD patients. In addition to routine clinical parameters, CKD273, a urinary proteomics-based classifier and its peptides were quantified. The baseline values were analyzed with regard to the clinical parameters and the occurrence of death or renal death during follow-up (3.6 years) as the main outcome measurements. None of the patients with CKD273<0.55 required dialysis or died while all fifteen patients that reached an endpoint had a CKD273 score >0.55. Unsupervised clustering analysis of the CKD273 peptides separated the patients into two main groups differing in CKD associated parameters. Among the 273 biomarkers, peptides derived from serum proteins were relatively increased in patients with lower glomerular filtration rate, while collagen-derived peptides were relatively decreased (p<0.05; Spearman). CKD273 was different in the groups with different renal function (p<0.003). The CKD273 classifier separated CKD patients according to their renal function and informed on the likelihood of experiencing adverse outcome. Recently defined in a large population, CKD273 is the first proteomic-based classifier successfully tested for prognosis of CKD progression in an independent cohort.

Item Type:Articles
Additional Information:The project carried out by the UROSYSTEOMICS consortium was partly funded by the Eurotransbio Program of the FP6, of the European Commission. AA and HM are members of the European Uraemic Toxin working group of the European Society of Artificial Organs (ESAO). HM was supported in part by EU Funding through EU-MASCARA (HEALTH-2011-278249) and SysKID (HEALTH–F2–2009–241544). No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Glasgow Author(s) Enlighten ID:Delles, Professor Christian and Mischak, Professor Harald
Authors: Argiles, A., Siwy, J., Duranton, F., Gayrard, N., Dakna, M., Lundin, U., Osaba, L., Delles, C., Mourad, G., Weinberger, K. M., and Mischak, H.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:PLoS ONE
Publisher:Public Library of Science
ISSN (Online):1932-6203
Published Online:14 May 2013
Copyright Holders:Copyright © 2013 Argiles et al.
First Published:First published in PLoS ONE 8(5):e62837
Publisher Policy:Reproduced under a creative commons license

University Staff: Request a correction | Enlighten Editors: Update this record